Abstract:
Objective To investigate the clinical value of 125I radioactive seed interstitial implantation in the treatment of advanced pancreatic cancer.
Methods The pain classification, solid tumor response evaluation criteria, and tumor markers(carbohydrate antigen CA242 and CA19-9) were examined in 97 patients with advanced pancreatic cancer by using ultrasound-guided 125I particle implantation surgery to evaluate the complications and adverse reactions of the tool.
Results Comparison among preoperative state, 1 week, 2 weeks, 1 month and 3 months post-surgery revealed significant differences in pain scores(χ2=0.018, 0.022, 0.034, 0.045, all P < 0.05); 8 cases had complete remission, 46 cases had partial remission, 34 cases were stable, and 9 cases progressed. The total effectiveness rate was 55.67%(54/97); moreover, comparison among the preoperative state, 1 month, and 3 months post-surgery indicated significant differences in the serum levels of CA19-9 and CA242(χ2=0.027, 0.029, 0.017, 0.022, all P < 0.05). After treatment, the median survival time was(8.0±4.5) months. No serious complications and adverse reactions were observed.
Conclusion 125I radioactive particle implantation for the treatment of advanced pancreatic cancer using ultrasound-guided surgery had curative effects, high safety, and significant pain relief.